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The mouse hepatitis virus (MHV) spike glycoprotein mediates attachment of the virus to the MHV receptor, the murine
biliary glycoprotein (BGP) carcinoembryonic antigen. Monoclonal antibody CC1 directed against BGP specifically inhibited
infection of DBT, Sac-, GT1-7, and OBL21 cells by wild-type MHV-4 and the neuron-adapted variant OBLV60. Binding to this
receptor was necessary to establish infection by cell-free MHV; however, the presence of BGP was not required for infection
by cell-associated virus. Cell-associated infection induced syncytium formation on Vero and BHK cells, which lack murine
BGP; this activity was not inhibited by monoclonal antibody CC1. Antibody CC1 also did not prevent syncytium formation
on DBT cells, which bear BGP. In infectious center assays, the MHV-4 variant OBLV60, which exhibits acid-dependent
fusion, spread to cells lacking BGP only when exposed to acidic media. Therefore, spike-mediated fusion was required for
BGP-independent spread of MHV infection. Furthermore, BGP-independent, cell-associated spread of MHV-4 was prevented
by monoclonal antibodies 5A13.5 and 5B19.2 directed against the spike glycoprotein, but not by other neutralizing and
nonneutralizing anti-spike antibodies. Expression of spike glycoprotein by recombinant vaccinia virus resulted in fusion of
BGP-negative cells; monoclonal antibodies 5A13.5 and 5B19.2 strongly inhibited spike-mediated fusion in this assay.
q 1996 Academic Press, Inc.
INTRODUCTION likely contains the receptor-binding domain. The carboxy-
terminal S2 portion of S is anchored in the viral mem-
Virus infection of cells is initiated through the interac-
brane by a hydrophobic transmembrane domain. Heptad
tion of one or more virion components with receptor mol-
repeat sequences in S2 are thought to fold into a-helices
ecules on the cell surface. Cellular receptors have been
that associate with one another in a coiled coil, formingidentified for several viruses and the specificity and affin-
the stalk of the oligomeric peplomer (de Groot et al.,ity of the virus–receptor interaction can dictate the
1987). In contrast to the fusion proteins of several othercourse of infection in vivo. The tissue distribution and
enveloped RNA viruses, cleavage of the murine coronavi-availability of receptors are primary determinants of viral
rus spike glycoprotein does not unmask an apparenttropism and influence viral pathogenesis. Subsequent to
N-terminal hydrophobic fusion peptide. The S2 heptadreceptor binding, viruses enter the cell through fusion
repeat region has, however, been shown to contain resi-either at the plasma membrane or in endosomal vesicles.
dues that influence the pH dependence of fusion (Gal-Internalization of virus may also be facilitated by addi-
lagher et al., 1991).tional low or high affinity interactions between virion pro-
The receptors for mouse hepatitis virus (MHV) areteins and cell surface molecules (Fuller and Spear, 1987;
members of the murine biliary glycoprotein family (BGP),Weiss, 1992; Wickham et al., 1993).
which are carcinoembryonic antigens (CEA) in the immu-The coronaviruses share in common a virion structure
noglobulin superfamily (Williams et al., 1990, 1991). Twomarked by distinctive peplomers that extend 200 A˚ from
murine bgp genes have been characterized, bgp1 andthe surface of the virion (Sturman et al., 1980). The
bgp2 (Nedellec et al., 1994). Through stable or transientpeplomer comprises a homotrimer of spike (S) glycopro-
expression of transfected cDNA, four isoforms of BGP1teins (Delmas and Laude, 1990) and mediates both virus
and one isoform of BGP2 have been shown to renderattachment and membrane fusion. Glycoprotein S is a
resistant cells susceptible to infection by MHV (Dveksler180-kDa class I integral membrane protein that is post-
et al., 1991, 1993; Yokomori and Lai, 1992a; Nedellec ettranslationally cleaved into two 90-kDa fragments called
al., 1994); however, in some cases an additional cellularS1 and S2 (Sturman et al., 1985). The amino-terminal S1
factor may be necessary for viral entry (Yokomori andportion forms the globular head of the peplomer and
Lai, 1992b; Yokomori et al., 1993). The N-terminal domain
of BGP, which displays additional polymorphism due to
1 To whom correspondence and reprint requests should be ad- allelic variation, functions in virus binding (Dveksler etdressed at The Scripps Research Institute, Department of Neurophar-
al., 1993). Monoclonal antibody CC1, directed againstmacology, 10666 N. Torrey Pines Road (CVN-8), La Jolla, CA 92037.
Fax: (619) 784-7369. the N-terminal domain, has been shown to block virion
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attachment, and thereby inhibit infection of cultured fibro- born CD1 mice (Ryder et al., 1990), and GT1-7, a murine
hypothalamic neuronal cell line (Mellon et al., 1990), wereblasts (Williams et al., 1990; Dveksler et al., 1991, 1993).
A CEA molecule in the pregnancy-specific glycoprotein maintained in DMEM/10% fetal bovine serum. All media
solutions were supplemented with 25 mM HEPES and 2subgroup can also serve as a receptor for some strains
of MHV, but not for the neurotropic MHV-4 (JHM) strain mM L-glutamine.
(Chen et al., 1995).
VirusIt has been demonstrated previously that the presence
of BGP (formerly called CEA-related MHV receptor) is The MHV-4 strain of virus was originally obtained from
not required for cell-to-cell spread of MHV-4 infection M. Haspel (Haspel et al., 1978) and is routinely passaged
(Gallagher et al., 1992). Cells lacking BGP were produc- in Sac- cells. The OBLV60 variant was isolated on Day
tively infected through fusion into virus-induced syncytia. 60 of a persistent MHV-4 infection established in OBL21a
Cell fusion was shown to be mediated by the spike glyco- cells (Gallagher et al., 1991).
protein. Specifically, MHV syncytia developed on mono-
layers of BHK and RK13 cells when these cells were Antibodies
cocultured with small numbers of monodispersed MHV-
The generation and characterization of monoclonalinfected DBT cells. BHK cells are resistant to MHV infec-
antibodies against MHV-4 and the production of ascitestion, but BHK cells transfected with BGP supported MHV
fluid has been previously described (Collins et al., 1982;infection (Dveksler et al., 1991), indicating that BHK cells
Buchmeier et al., 1984). The specificity of the monoclonalpossess all of the components required for MHV replica-
antibodies against the nucleocapsid (N), membrane (M),tion except the receptor. The cell-associated spread of
or S proteins are as follows: 4B6.2 (N), 5A5.2 (M), 5B11.2infection to the BGP-negative BHK and RK13 cells led to
(M), 5A13.5 (S), 5B19.2 (S), 4B11.6 (S), 5B93.3 (S), 5B21.5the production of 250 and 21 times more infectious virus,
(S), 5B207.7 (S), and 5B216.8 (S). Monoclonal antibody 1-respectively, than duplicate cultures without a target cell
1.3 recognizing the lymphocytic choriomeningitis virusmonolayer (Gallagher et al., 1992). Therefore, through
(LCMV) nucleocapsid protein was used as a control anti-cell-to-cell spread of infection, MHV can bypass the re-
body against an unrelated antigen (Buchmeier et al.,ceptor-binding event normally required for extracellular
1981). Anti-BGP antibody CC1 hybridoma supernatantinfection.
was generously provided by Kathryn Holmes.In this report, we examined the receptor utilization by
the neurotropic strain MHV-4 and a neuron-adapted vari-
Plaque assays
ant, OBLV60, in cultured cells of neuronal and nonneu-
ronal origin. We demonstrate that although anti-BGP anti- Viral titers were determined by plaque assay in which
DBT cell monolayers in six-well culture plates were inoc-body CC1 prevents MHV-4 and OBLV60 infection of sev-
eral cell types, it does not block cell-associated spread ulated with serial log or half-log dilutions of virus. After
a 1-hr absorption period, the inoculum was removed andof infection. This finding supports our contention that
the cell-associated spread of MHV does not require the replaced with overlay medium (DMEM, 1% calf serum,
0.5% SeaKem agarose). After plaque development, thepresence of BGP. Further, we investigated the role of
spike-mediated fusion in BGP-independent, cell-associ- monolayers were fixed with5% paraformaldehyde, then
stained with 0.1% crystal violet after removal of the aga-ated MHV infection and found that this alternate mecha-
nism of spread requires spike-mediated fusion activity. rose overlay.
To quantitate the capacity for anti-BGP antibody CC1We used vaccinia-based expression of spike glycopro-
tein to assay fusion activity that is independent of recep- to inhibit MHV-4 infection, plaque reduction assays were
performed as follows. DBT or Sac- cell monolayers intor interaction and demonstrate that monoclonal antibod-
ies which inhibit fusion also prevent BGP-independent, six-well culture plates were incubated with either no anti-
body or half-log dilutions of antibody CC1 for 1 hr beforecell-associated spread of MHV infection.
and 2 hr after infection with a standardized inoculum of
MHV-4 (150 PFU). The inoculum was then removed andMATERIALS AND METHODS
replaced with overlay medium. Fixation and staining
Cells
were performed as described above. The ability of anti-
body CC1 to inhibit infection with MHV-4 or OBLV60 wasDBT murine astrocytoma (Hirano et al., 1978) and Sac-
Moloney sarcoma (Weiland et al., 1978) cell lines were also assessed microscopically. Confluent monolayers of
GT1-7, OBL21, DBT, or Sac- cells were pretreated for 1maintained in DMEM with 8% calf serum (Hyclone). BHK-
21 cells (baby hamster kidney) were maintained in hr at 377 with antibody CC1 at twice the dilution indicated,
before addition of an equal volume of virus. After 16 toDMEM/8% calf serum with 0.11 TPB and 0.5% glucose.
Vero E6 cells (African green monkey kidney) were main- 20 hr of incubation at 377, cells were fixed and processed
for immunofluorescence.tained in MEM/10% fetal bovine serum (Irvine Scientific)
with 0.25% NaHCO3 . OBL21, a retrovirus-transformed The neutralizing titer of ascites fluid containing mono-
clonal antibody against MHV-4 was quantitated byneuronal cell line derived from the olfactory bulb of new-
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plaque reduction assay as follows. Ascites fluids were
serially diluted in DMEM and mixed with an equal volume
(0.2 ml) of a standardized inoculum of MHV-4 (100 PFU).
The virus–antibody mixtures were incubated at 47 for 1
hr, then used to inoculate DBT cell monolayers in six-
well culture plates. Following a 1-hr absorption at 377,
the inoculum was removed and replaced with overlay
medium. Fixation and staining were performed as de-
scribed above.
The capacity of ascites fluid to inhibit cell–cell fusion
was quantitated by plaque reduction assay. DBT cell
monolayers were incubated with a standardized inocu-
lum of MHV-4 (100 PFU) for 1 hr at 377. The inoculum
was then removed and replaced with overlay medium
containing ascites fluid at serial dilutions. Fixation and
FIG. 1. Inhibition of MHV-4 infection of DBT and Sac- cells with anti-staining were performed as described above.
BGP monoclonal antibody CC1. DBT or Sac- cell monolayers were
incubated with the indicated dilutions of antibody CC1 for 1 hr before
and 2 hr after infection with MHV-4. Culture media were then removedIndirect immunofluorescence
and replaced with agarose overlay media. Following incubation at 377
for 2 days, cells were fixed with paraformaldehyde, then stained withCells that were grown on glass coverslips or Nunc
crystal violet.Lab-Tek chamber slides were fixed with 10% zinc-forma-
lin for 5 min at room temperature, permeabilized with 2%
NP-40 for 10 min, then blocked with 5% normal goat Expression of recombinant S glycoprotein
serum (Vector Laboratories) for 15 min or more. The cells
BHK or DBT cell monolayers grown on glass coverslipswere bathed for 1 hr or more with a cocktail of anti-MHV
were co-infected with the recombinant vaccinia virus en-antibodies (4B6.2, 5A5.2, and 5B19.2 or 5A13.5, recogniz-
coding bacteriophage T7 RNA polymerase, vTF7.3ing nucleocapsid, membrane, and spike proteins, re-
(Fuerst et al., 1986), and a recombinant vaccinia virusspectively) at a 1:100 dilution in phosphate-buffered
that has the MHV-4 spike cDNA under the control of thesaline (PBS) containing 1% normal goat serum, then incu-
T7 RNA polymerase promoter (vv-S). The spike vacciniabated for 1 hr with a TRITC-conjugated, sheep anti-
recombinant had been derived through homologous re-mouse antibody (Accurate), also diluted in PBS con-
combination between vaccinia DNA and MHV-4 spiketaining 1% normal goat serum. Cells were mounted in
cDNA inserted into the pTM-1 vector (T. M. Gallagher and90% glycerol containing 25 mg/ml 1,4-diazobicyclo-2,2,2-
M. J. Buchmeier, unpublished data, 1994). Expression ofoctane in PBS and visualized by fluorescence micros-
recombinant spike glycoprotein was detected by indirectcopy.
immunofluorescence. For specified experiments, anti-
spike monoclonal antibodies 5A13.5, 5B19.2, 4B11.6,Infectious center assay
5B93.3, 5B21.5, 5B207.7, or 5B216.8 or control antibodies
directed against BGP (CC1), the membrane proteinAdherent DBT cells were removed from tissue culture
(5B11.5), nucleocapsid protein (4B6.2), or the LCMV nu-flasks by treatment with Nonenzymatic Cell-Dissociation
cleocapsid protein (1-1.3) were included at a 1:100 orSolution (Sigma) and infected with MHV-4 or OBLV60 in
1:500 dilution.suspension at a multiplicity of 5 PFU per cell. The cells
were incubated at 377 for 1 hr, then washed extensively
RESULTSin cold PBS or OptiMem serum-free medium (Gibco). The
infected cells were serially diluted in OptiMem media
Anti-BGP antibody CC1 inhibits both MHV-4 and
containing monoclonal antibody CC1 (1:100 dilution),
OBLV60 infection
then seeded onto untreated glass coverslips or cov-
erslips covered with confluent BHK, Vero, or DBT cell Dveksler et al. (1991) have demonstrated that BGP is
a functional receptor for MHV strain A59 by inhibitingmonolayers. All target cell monolayers had been pre-
treated with monoclonal antibody CC1 (1:50 dilution) for infection with the anti-BGP monoclonal antibody CC1. To
confirm that the neurotropic MHV-4 strain also uses this1 hr; a 1:100 dilution of antibody CC1 was present
throughout the course of the experiment. For specified receptor, we performed receptor-blocking experiments
with monoclonal antibody CC1. Figure 1 shows that anti-experiments, anti-spike monoclonal antibody 5A13.5,
5B19.2, 4B11.6, 5B93.3, or 5B21.5 was also included at body CC1 led to a reduction of MHV-4 plaque formation
assayed on two different murine cell lines. Complete inhi-a 1:100 dilution. At 20 hr postinfection, the cells were
fixed and infected cells were visualized by indirect immu- bition was measured at dilutions of antibody CC1 less
than 1002.5. The 50% reduction in plaque number wasnofluorescence.
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FIG. 2. Inhibition of MHV-4 infection of GT1-7 cells and OBLV60 infection of GT1-7 and OBL21 cells by anti-BGP monoclonal antibody CC1. Cell
cultures were either (A, D, G) untreated or pretreated for 1 hr with antibody CC1, which was present at dilutions of (B, E) 1:10, (H) 1:20, or (C, F, I)
1:100 throughout the course of infection. Confluent cell monolayers were infected with MHV-4 (A–C) or OBLV60 (D–I). Following a 20-hr incubation,
MHV antigen was detected by indirect immunofluorescence.
greater than 1003.5 for antibody CC1 on both cell lines. The ability of anti-BGP monoclonal antibody CC1 to
inhibit infection with MHV-4 or OBLV60 was also as-The dose-dependent plaque reduction indicates that
antibody CC1 blocks the MHV receptor that is utilized by sessed microscopically, in which case the extent of infec-
tion was visualized following indirect immunofluorescentMHV-4 in both DBT and Sac- cells.
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staining of viral antigen. MHV infection of the neuronal supports the conclusion that cell-associated spread of MHV
can occur without BGP serving as the MHV receptor.cell lines GT1-7 and OBL21 does not cause the formation
of discernible plaques; however, there is clearly a dose-
Spike-mediated fusion is required for BGP-dependent inhibition of MHV-4 and OBLV60 infection of
independent cell-to-cell spread of MHV infectionthese cell lines by monoclonal antibody CC1. Represen-
tative examples in which confluent monolayers of these
OBLV60 is a fusion variant of MHV-4 that arose during
cells were inoculated with MHV-4 or OBLV60 with or
persistent infection of the OBL21a cell line (Gallagher et
without monoclonal antibody CC1 pretreatment are
al., 1991), a neuronal cell line that is refractory to MHV-
shown in Fig. 2. At a 1002 dilution of antibody CC1, in
induced cell fusion. Due to three amino acid mutations
fields of more than 105 cells, no MHV-4-infected GT1-7
that occurred in the heptad repeat region of S2, the
cells were detected (Fig. 2C), and the number of OBLV60-
OBLV60 spike glycoprotein requires acid activation in
infected GT1-7 (Fig. 2F) or OBL21 (Fig. 2I) cells detected
order to mediate membrane fusion (Gallagher et al.,
was reduced by more than 50% compared to the corre-
1991). Consequently, infection of fusion-sensitive cells
sponding cultures without antibody CC1 (Figs. 2D and
with OBLV60 leads to syncytium formation only in acidic
2G). At higher concentration of antibody CC1, only an
culture medium.
occasional OBLV60-infected GT1-7 (Fig. 2E) or OBL21
To assess the role of fusion in BGP-independent, cell-
(Fig. 2H) cell was detected. Together, these results dem-
associated spread of MHV, we tested whether infection
onstrate that infection of both neuronal and nonneuronal
spreads in a BGP-independent manner from cells in-
cells by cell-free MHV-4 and OBLV60 requires the pres-
fected with the OBLV60 acid-dependent fusion variant.
ence of accessible BGP.
An infectious center assay was performed in which
OBLV60-infected DBT cells were seeded with (Figs. 3F
Anti-BGP antibody CC1 does not prevent cell-to-cell and 3H) and without (Figs. 3E and 3G) an underlying
spread of MHV infection monolayer of confluent BGP-negative BHK or Vero target
cells. As above, monoclonal antibody CC1 was present
Cell-associated spread of MHV to cells that lack murine
throughout the course of the experiment. In neutral pH
BGP has been demonstrated with an infectious center
culture medium, OBLV60 infection remained isolated to
assay in which infection spread from MHV-infected DBT
the single cells of the overlay and failed to spread to
cells to BGP-negative target cell monolayers (Gallagher et
receptor-negative target cells (Fig. 3F). However, when
al., 1992). To further test the role of BGP in cell-associated
exposed to acidic (pH 5.0) medium for 1 hr, small syncytia
spread of MHV infection, infectious center assays were
developed as a result of one round of fusion between
performed with inclusion of the receptor-blocking mono-
the OBLV60-infected cells and adjacent BGP-negative
clonal antibody CC1 in the culture media. Confluent BHK,
cells; return to neutral pH prevented the further spread
Vero, and DBT cell monolayers were preincubated with
of infection. The ability of the OBLV60 fusion variant to
antibody CC1 for 1 hr, then overlaid with a suspension of
spread to BGP-negative cells only at acidic pH demon-
MHV-4-infected DBT cells. At 20 hr postinfection, infected
strates that spike glycoprotein fusion capability is re-
DBT cells plated without an underlying monolayer were
quired for BGP-independent, cell-associated spread of
widely dispersed and remained single cells (Figs. 3A and
MHV infection.
3C), whereas large syncytia were evident in the cultures
with BHK (Fig. 3B), DBT (Fig. 3D), or Vero (data not shown) BGP-independent, cell-associated spread of MHV-4 is
target cell monolayers. The number of syncytia was approx- prevented by fusion-inhibiting anti-spike monoclonal
imately equal to the number of infected single cells in the antibodies
cultures without an underlying monolayer (data not shown),
consistent with a cell-to-cell rather than extracellular mode We have previously reported the generation and char-
acterization of a panel of neutralizing and nonneutralizingof virus transmission. The presence of syncytia indicates
that infection spread from the primary infected DBT cells monoclonal antibodies directed against the MHV-4 spike
glycoprotein (Collins et al., 1982; Buchmeier et al., 1984).to the BHK, Vero, and DBT cell monolayers, despite the
presence of antibody CC1 in the culture medium. The inabil- The results of plaque reduction assays quantitating the
neutralization and fusion inhibition titers for monoclonality of monoclonal antibody CC1 to prevent infection of target
cell monolayers in these infectious center assays further antibody ascites preparations used in this study are
FIG. 3. Cell-associated spread of MHV infection despite the presence of anti-BGP antibody CC1 and BGP-independent spread of cell-associated
OBLV60 at acidic pH. DBT cells were infected with (A–D) MHV-4 or (E–H) OBLV60 in suspension for 1 hr, then washed extensively to remove
unbound virus. Aliquots of infected DBT cells were overlaid onto blank coverslips (A, C, E, G), confluent BGP-negative BHK cell (B, F), or Vero cell
monolayers (H) or confluent BGP-positive DBT cell monolayers (D). Following an 18-hr incubation, the cells shown in (H) were exposed to MES-
buffered DMEM (pH 5.0) for 1 hr. Small OBLV60-induced syncytia that appeared after acid exposure are marked with arrows and shown enlarged
in the inset. Antibody CC1 was present at 1:100 dilution in all cultures throughout the experiment. MHV antigen was detected by indirect immunofluo-
rescence at 20 hr postinfection.
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TABLE 1shown in Fig. 4. The plaque reduction values measured
for antibody dilutions of 1:100 are listed in Table 1. Mono- Functional Activities of Anti-Spike Monoclonal Antibodies
clonal antibodies 5B19.2, 5A13.5, and 4B11.6 were
PRA vv-Sstrongly neutralizing, reducing plaque formation 100% at
Monoclonal fusion fusion BGP-IS In vivoa 1:100 dilution. Antibodies 5B93.3 (78.4%) and 5B21.5
antibody Neutralizationa inhibitiona inhibitiona inhibitiona protectionb(48.6%) were moderately and weakly neutralizing, respec-
tively; antibody 5B207.7 (4.4%) was essentially nonneu- 5A13.5 100% 90.0%c / / /
tralizing (Fig. 4A). Only antibodies 5A13.5 (90%) and 5B19.2 100% 81.6%c / / /
4B11.6 100% 58.8%c 0 //0 05B19.2 (81.6%) strongly inhibited cell fusion. Monoclonal
5B93.3 78.4% 9.4% 0 0 0antibodies 4B11.6 (58.8%) and 5B21.5 (36.7%) partially
B521.5 48.6% 36.7% 0 0 0inhibited fusion, whereas antibodies 5B93.3 (9.4%) and
B5207.7 4.4% 0.0% 0 ND 0
5B207.7 (0%) did not prevent fusion (Fig. 4B). The plaques
were significantly smaller than normal in the assays with a Antibody dilutions 1:100; PRA, plaque-reduction assay; vv-S, vac-
cinia virus-expressed spike glycoprotein; BGP-IS, BGP-independentantibody 5A13.5 at all dilutions, or antibodies 5B19.2 or
spread; ND, not determined.4B11.6 at dilutions of 1002, 1002.5, and 1003.
b Buchmeier et al., 1984.To examine the structural and functional features of c Small plaque morphology.
the spike glycoprotein that are important for receptor-
independent syncytia formation, we tested the ability of
anti-spike monoclonal antibodies to interfere with BGP-
independent spread of MHV-4 infection in an infectious
center assay. MHV-4-infected DBT cells were bathed in
media containing individual anti-spike monoclonal anti-
bodies (1:100 dilution) before being seeded onto conflu-
ent BHK cell monolayers. Both anti-spike monoclonal
antibodies and anti-receptor antibody CC1 were present
at a 1:100 dilution throughout the course of the experi-
ment. Two antibodies, 5A13.5 and 5B19.2, routinely pre-
vented MHV-induced syncytia formation; infectious cen-
ters remained mononuclear (Figs. 5B and 5C). Mono-
clonal antibody 4B11.6 inhibited, but did not consistently
prevent BGP-independent spread of MHV-4. In some ex-
periments, a few small syncytia were detected in the
presence of antibody 4B11.6; however, most infectious
centers remained mononuclear (Fig. 5D). Monoclonal an-
tibodies 5B93.3 and 5B21.5 had no apparent effect on
BGP-independent spread of MHV-4. In the presence of
antibodies 5B93.3 (Fig. 5E) or 5B21.5 (Fig. 5F), cell–cell
fusion led to the formation of syncytia that were approxi-
mately the same size at the syncytia that developed in
the absence of anti-spike monoclonal antibodies (Fig. 5A)
and no mononuclear infectious centers were detected.
Inhibition of recombinant spike-mediated fusion by
anti-spike monoclonal antibodies
MHV-induced fusion activity can be mediated by the
spike glycoprotein alone; no other viral components are
required (Pfleiderer et al., 1990; Gallagher et al., 1991). We
(Gallagher et al., 1992) and others (Taguchi et al., 1992)
have demonstrated that expression of recombinant MHV
FIG. 4. MHV-4 neutralization and inhibition of syncytia formation by spike glycoprotein leads to syncytia formation on both BGP-
anti-spike monoclonal antibodies. (A) Neutralization plaque-reduction positive and BGP-negative cells. Furthermore, there is no
assay. MHV-4 was incubated with the indicated dilutions of ascites qualitative difference in the degree of fusion induced by
fluid for 1 hr prior to infection of DBT cells. (B) Fusion inhibition plaque-
vaccinia virus-expressed recombinant spike glycoproteinreduction assay. DBT cell were infected with MHV-4 for 1 hr, then
on DBT (BGP-positive) or BHK (BGP-negative) cells whenoverlaid with overlay medium containing ascites fluid at the indicated
dilutions. antibody CC1 is included in the culture medium (data not
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FIG. 5. Prevention of BGP-independent, cell-associated spread of MHV-4 by fusion-inhibiting anti-spike monoclonal antibodies 5A13.5 and 5B19.2.
MHV-4-infected DBT cells in suspension were treated with anti-spike monoclonal antibodies (1:100) and overlaid onto confluent BHK cell monolayers
in the presence of antibody CC1. (A) No anti-spike antibody, (B) 5A13.5, (C) 5B19.2, (D) 4B11.6, (E) 5B93.3, and (F) 5B21.5. Viral antigen was detected
by indirect immunofluorescence.
shown). These results demonstrate that expression of re- antibodies 5A13.5 or 5B19.2 were present; antibodies
5A13.5 or 5B19.2 inhibited spike-mediated fusion in thiscombinant spike glycoprotein in BGP-negative cells pro-
vides an assay for fusion that is independent of receptor assay at both 1:100 and 1:500 dilutions. Representative
examples of vv-S-induced syncytia and fusion inhibition byinteractions. Here, we used this assay to evaluate the ca-
pacity of anti-spike monoclonal antibodies to specifically antibody 5A13.5 are shown in Fig. 6.
In summary, BGP-independent spread of MHV-4 infec-block spike-mediated fusion.
BHK cells were co-infected with recombinant vaccinia tion was inhibited by anti-spike monoclonal antibodies
that strongly inhibit MHV-induced syncytium formationviruses expressing T7 RNA polymerase (Fuerst et al., 1986)
and the MHV-4 spike glycoprotein (vv-S) in the presence of and spike-mediated cell fusion, but not by neutralizing
or nonneutralizing antibodies that do not inhibit fusion.1:100 or 1:500 dilutions of the following antibodies: 5A13.5,
5B19.2, 4B11.6, 5B21.5, 5B93.3, 5B207.7, 5B216.8, 5B11.5
DISCUSSION(anti-M), 4B6.2 (anti-N), CC1 (anti-BGP), and 1-1.3 (anti-
LCMV NP). Recombinant spike glycoprotein expression We have demonstrated that cell-associated MHV can
bypass the requirement for binding to its primary recep-caused syncytia formation in all cases tested except where
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FIG. 6. Inhibition of recombinant spike-mediated fusion by anti-spike monoclonal antibody 5A13.5. Recombinant MHV-4 spike glycoprotein was
expressed by a vaccinia virus-based system with or without the presence anti-spike monoclonal antibodies. (A) No anti-spike antibody, (B) 5A13.5
(1:500), (C) 5B93.3 (1:100), and (D) 5B21.5 (1:100). Spike antigen was detected with indirect immunofluorescence.
tor, BGP, and thereby spread to cells that are resistant We further demonstrated that BGP-independent, cell-
associated spread of MHV requires viral fusion capabil-to infection by cell-free MHV. Anti-BGP antibody CC1,
which blocked infection by MHV virions, failed to prevent ity; the acid-dependent MHV fusion variant OBLV60
spread through a BGP-independent mechanism only un-cell-associated spread of MHV to BGP-negative or BGP-
positive cells. The capacity for BGP-independent, cell- der conditions permissive for fusion. Viral fusogenicity is
a function of the spike glycoprotein and expression ofassociated spread may permit greater dissemination of
infection in vivo and consequently may augment viru- recombinant spike glycoprotein alone is sufficient to in-
duce syncytia formation. Recombinant MHV-4 spike gly-lence. We previously demonstrated that the MHV-4
strain, which is highly neurovirulent, spread to BGP-nega- coprotein fused BGP-negative cells and was unaffected
by anti-BGP antibody CC1; these results segregate thetive cells in culture more efficiently than the less neurovi-
rulent A59 strain (Gallagher et al., 1992); however, these receptor-binding and fusion activities of the MHV spike
glycoprotein. Theoretically, dissemination of MHV infec-two strains do differ significantly, particularly in the S1
domain of the spike glycoprotein, and therefore this ob- tion through a BGP-independent, cell-associated mecha-
nism in vivo provides the potential for spread of infectionservation does not conclusively demonstrate a correla-
tion between neurovirulence and capacity for receptor- to cells that lack BGP or despite the presence of neu-
tralizing antibodies. Only anti-spike monoclonal antibod-independent spread. In an in vivo prophylaxis experi-
ment, anti-BGP monoclonal antibody CC1 failed to fully ies 5A13.5 and 5B19.2 prevented BGP-independent, cell-
associated spread of MHV infection. These antibodiesprotect infected mice against encephalitis (Smith et al.,
1991). The inability of anti-BGP antibody to completely strongly inhibited spike-mediated fusion in MHV plaque
reduction assays and vaccinia-based expression experi-prevent spread of infection to the brain is not surprising
if a BGP-independent component of MHV spread oper- ments. Interestingly, in vivo administration of these same
two antibodies has been shown to attenuate MHV infec-ates in vivo. This alternate mechanism of spread may
also explain how MHV, which does not infect primate tion and protect against fatal encephalitis in mice (Buch-
meier et al., 1984). A summary of the functional featuresfibroblasts in culture (Compton et al., 1992), did infect
primates inoculated with a suspension of infected murine of several anti-spike monoclonal antibodies is presented
in Table 1.cells or brain homogenate (Murray et al., 1992).
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Information about the structural domains of the spike known to be affected by the lipid composition of the
plasma membrane (Daya et al., 1988; Roos et al., 1990).glycoprotein recognized by the antibodies used in this
study is limited. Monoclonal antibody 5B19.2 recognizes Other viruses that can mediate membrane fusion at
neutral pH may also have the capacity to spread througha linear epitope (Luytjes et al., 1989) located in an immu-
nodominant neutralization domain in a conserved region receptor-independent mechanisms. Interestingly, the fu-
sogenic transmembrane protein of HIV, gp41, has beenof S2 (Daniel et al., 1993). Antibodies 5A13.5 and 4B11.6
recognize topographically distinct, conformation-depen- reported to induce syncytium formation when expressed
in cells normally resistant to infection with HIV virions,dent epitopes (Talbot et al., 1984). Neuroattenuated MHV
variants V5A13 and V4B11 (Dalziel et al., 1986), which suggesting that receptor-independent, cell-associated
spread may also occur during HIV infection (Perez etescaped neutralization by antibodies 5A13.5 and 4B116,
respectively, have deletions in S1 (Parker et al., 1989; al., 1992). The capability of viruses to bypass binding to
primary receptors through, for example, the use of alter-Gallagher et al., 1990); however, it is not known whether
the monoclonal antibody contact residues lie within the nate receptors or virus-mediated cell–cell fusion needs
to be considered in the design of potential receptor-tar-deleted region or whether the deletions affect protein
conformation at other sites. Neutralization-resistant vari- geted antiviral agents.
ants with point mutations, rather than deletions, have
also been isolated (Gallagher et al., 1990); we are cur- ACKNOWLEDGMENTS
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